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SUMMARY
Whether the insulin resistance commonly observed in patients with inflammatory arthritis is a disease-specific 
feature and/or is limited to a disease phase (i.e., it occurs only during phases of high disease activity) is un-
known. 
Fifty-three rheumatoid arthritis (RA) and 44 psoriatic arthritis (PsA) patients were recruited consecutively 
along with 194 controls matched for age, sex and body mass index for a case-control study. All underwent 
an oral glucose tolerance test, the results of which were analysed to derive the following indexes: homeo-
static model of insulin resistance (HOMA-IR), insulin sensitivity index (ISI) and early insulin sensitivity index 
(EISI). These data were related to anthropometric, clinical and laboratory findings.
Metabolic parameters of patients and controls were similar. Neither inflammatory markers nor disease activity 
scores were related to glucose metabolism for the generality of RA and PsA patients; however, by restricting the 
analysis to the subset of RA patients with residual disease activity, an association emerged between erythrocyte 
sedimentation rate, on the one hand, and fasting insulin (β=0.46, p=0.047) and HOMA-IR (β=0.44, p=0.02), 
on the other. Moreover, C-reactive protein (CRP) levels were associated with plasma glucose and insulin levels 
measured 120 min after the glucose load (β=0.91, p=0.0003 and β=0.77, p=0.0006, respectively); ISI and EISI 
were predicted by CRP (β=-0.79, p=0.0006; β=-0.80, p=0.0001, respectively). The same did not hold true for 
PsA patients.
The association between systemic inflammation and insulin resistance indexes is a feature of RA with residual 
disease activity, not a universal feature of inflammatory arthritides.
Key words: Insulin sensitivity; Insulin resistance; Rheumatoid arthritis; Psoriatic arthritis; Oral glucose toler-
ance test.
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n	 INTRODUCTION
Comorbidities, including diabetes, have become a hot topic in the management 
of inflammatory arthritis (1). In this regard, 
an association has been reported between 
inflammation and insulin resistance in 
rheumatoid arthritis (RA) and psoriatic ar-
thritis (PsA) (2, 3). Since insulin resistance 
is one of the major drivers of cardiovascu-
lar diseases, which in turn are responsible 
for a significant morbidity and mortality 
burden among patients with inflammato-
ry arthritis (4), this proposed association 
may have important clinical implications. 
First and foremost, it would support the 
hypothesis that better disease control 
may extend its benefits on cardiovascular 
health. Indeed, both classical and biologi-
cal disease modifying anti-rheumatic drugs 
(DMARDs) improve insulin sensitivity (5, 
6), confirming that activation of inflamma-
tory pathways may impair insulin action. 
The mechanisms linking insulin resistance 
and inflammatory arthritis are debated, 
however, and very limited data on insulin 
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resistance dynamically investigated by an 
oral glucose tolerance test (OGTT) exist 
(7). Moreover, there is a paucity of data 
comparing glucose metabolism in RA vs 
PsA (8). With the present study, we aim to 
fill these gaps.
n	 MATERIALS AND METHODS
In the present case-control study, cases were 
consecutively recruited at an immune-rheu-
matology clinic of an academic hospital, 
between November 2014 and June 2015. 
Inclusion criteria were: age >18, diagnosis 
of either RA (according to ACR/Eular clas-
sification criteria 2010 (9)) or PsA (accord-
ing to CASPAR criteria (10)). Patients were 
excluded if previously diagnosed as diabet-
ics. The study was conducted according to 
the principles of the Helsinki Declaration.
The following data were collected:
• Demographic and clinical characteris-
tics: age, sex, active anti-rheumatic treat-
ment, steroid treatment, cumulative dose 
of steroids administered in the preceding 
3 and 12 months, comorbidities. The Dis-
ease Activity Score (DAS28), the Clinical 
Disease Activity Index (CDAI) and the 
Simplified Disease Activity Index (SDAI) 
were used to assess disease activity in RA; 
patients affected by PsA were classified as 
achieving minimal disease activity when 5 
of the 7 following criteria were met: ten-
der joint count ≤1; swollen joint count ≤1; 
Psoriasis Activity and Severity Index ≤1 or 
body surface area ≤3%; patient pain visual 
analogue score (VAS) ≤15; patient global 
disease activity VAS ≤20; health assess-
ment questionnaire ≤0.5; tender entheseal 
points ≤1 (11). 
• Anthropometric data: weight (to the near-
est 0.1 kg) and height (to the nearest cm) 
were measured with the patient wearing only 
light underwear; body mass index (BMI) 
was calculated according to the formula 
weight (kg)/height (m)2, and interpreted ac-
cording to WHO classification (http://www.
euro.who.int/en/health-topics/disease-pre-
vention/nutrition/a-healthy-lifestyle/body-
mass-index-bmi). Waist circumference was 
measured halfway between the costal edge 
and the crista. 
• Laboratory data: erythrocyte  sedimenta-
tion rate (ESR) was measured by the West-
ergren method (VES-Matic Cube 200”, 
DIESSE Diagnostica senese, Siena, Italy); 
C-Reactive Protein (CRP) was dosed by 
immunoturbidimetric analysis (Advia 1800 
chemistry system, Siemens healthcare and 
diagnostics, Leverkusen, Germany). All pa-
tients underwent a standard OGTT: follow-
ing at least 12 hours of fasting, 75 grams 
of glucose were administered after a first, 
baseline, blood sampling. A second sample 
was taken after 2 hours. Plasma glucose 
was measured by the hexokinase-reaction 
(Advia 1800 chemistry system, Siemens 
healthcare and diagnostics, Leverkusen, 
Germany), while insulin plasma concen-
tration was determined by immunometric 
sandwich chemiluminescence (Advia Cen-
taur, Siemens healthcare and diagnostics, 
Leverkusen, Germany). The results of the 
OGTT were interpreted according to ADA 
recommendations (12), as follows: normal 
fasting plasma glucose (FPG) if <100 mg/
dl (5.6 mmol/l); impaired FPG (IFG) if 
FPG was 100–125 mg/dl (6.9 mmol/l); im-
paired glucose tolerance (IGT) if 2-h post-
OGTT plasma glucose was 140–199 mg/dl 
(7.8-11.0 mmol/l); T2DM if FPG was ≥126 
mg/dl (≥7 mmol/l) on two days apart, or 
if 2-h post-OGTT plasma glucose (2hPG) 
was ≥200 mg/dl (≥11.1 mmol/l). Glycated 
haemoglobin (HbA1c) was simultane-
ously measured by a chromatographic as-
say (Variant Biorad, Hercules, California, 
USA). HbA1c values of 5.7 and 6.5% were 
considered as thresholds for normal glu-
cose metabolism and T2DM, respectively. 
Finally, the following insulin sensitivity 
and resistance indices were derived:
– Insulin resistance was calculated by the 
homeostatic model of insulin resistance 
(HOMA-IR) as fasting insulin (FPI, 
μU/m) × [FPG (mmol/l)/22.5] (13);
– Insulin sensitivity index (ISI) (14) as 2/
[FPG+2hPG)/178 × (FPI+2hPI)/46.94 
+ 1];
– Early Insulin Sensitivity Index (EISI) 
(15): EISI = 0.156 − 0.0000459 × 2hPI 
− 0.000321 × FPI − 0.00541 × 2hPG.
For each patient, two sex and age (+/- 2.5 
years) matched controls were selected 
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same academic hospital. Controls were 
also matched for presence/absence of arte-
rial hypertension and belonged to the same 
World Health Organization BMI category 
of cases.
Data were recorded in a database and ana-
lysed using the statistical software pack-
age MedCalc v. 9.3.8.0 (MedCalc Soft-
ware, Broekstraat 52, 9030, Mariakerke, 
Belgium). A significant departure from 
normal distribution was verified by the 
D’Agostino-Pearson test for continuous 
variables; accordingly, the measures of 
centrality and dispersion of data chosen 
were median and interquartile range [IQR]. 
Continuous variables of interest in groups 
(controls, RA and PsA) were compared by 
the Kruskal-Wallis (K-W) test. The distri-
bution of categorical variables was com-
pared between groups by Pearson’s χ2. The 
existence of an association between poten-
tial predictors of glucose metabolism and 
blood glucose parameters was investigated 
by univariate analysis; the corresponding 
putative predictors of glucose metabolism 
were then used to build multivariate mod-
els of prediction. The significance level 
chosen for each test was 0.05 (two-tails).
n	 RESULTS
The study population included 53 consecu-
tive patients with RA, 44 with PsA and 194 
controls matched for age, sex and BMI. 
Demographic features, metabolic and dis-
ease-related parameters are reported in Ta-
ble I. We found no significant differences 
comparing metabolic parameters of pa-
tients and controls (see Table I for details).
We then performed a univariate analysis 
on RA patients, to search for predictors 
(age, BMI, WC, ESR, CRP, daily pred-
nisone dose, disease duration, disease 
activity, DAS28, CDAI, SDAI) of FPG, 
2hPG, FPI, 2hPI, Hb1Ac alteration and of 
Table I - Demographic, metabolic and disease related features of the population.
Controls (194) Rheumatoid Arthritis (53)
Psoriatic 
Arthritis (44)
Anova (K-W)* 
or χ2 (pearson)$
Age (years) 56 [48-64] 57 [50-67] 54 [48-60] p=0.025*
Sex (M/F) 58/136 9/44 20/24 p=0.010$
BMI (kg/m2) 26.9 [23.8-31.1] 26.8 [23.3-31.4] 27.7 [24.3-32.5] p=0.259*
WC (cm) 90 [80-101] 87 [75-98] 90 [81-102] p=0.241*
FPG (mmol/l) 5.19 [4.89-5.67] 5.06 [4.72-5.61] 5.22 [4.94-5.72] p=0.279*
2hPG (mmol/l) 5.97 [5.11-7.61] 5.61 [5.00-6.83] 6.14 [4.94-7.67] p=0.355*
FPI (pmol/l) 71.8 [47.6-105.4] 81.6 [52.0-114.0] 76.5 [50.5-114.8] p=0.510*
2hPI (pmol/l) 405.6 [258.4-808.3] 456.1 [258.4-719.5] 324.8 [159.5-739.7] p=0.359*
HOMA-IR 2.25 [1.52-3.60] 2.53 [1.70-3.59] 2.53 [1.69-3.87] p=0.696*
HbA1c 5.6 [5.4-5.9] 5.6 [5.3-6.0] 5.5 [5.3-5.8] p=0.440*
ISI 0.74 [0.45-1.02] 0.76 [0.53-1.03] 0.89 [0.46-1.17] p=0.475*
EISI 0.08 [0.04-0.10] 0.08 [0.06-0.10] 0.08 [0.05-0.10] p=0.955*
ADA categories  
(NGT/IFG/IGT/IFG-IGT/diabetes) 118/12/32/20/12 35/1/9/4/4 27/2/7/5/3 p=0.971$
Prednisone use (y/n) 0/194 33/20 3/41 p=0.0001$
Median daily dose (mg) 0.00 [0.00-0.00] 1.46 [0.47-3.50] 0.00 [0.00-0.00] p<0.0001*
Disease activity (active/remission) n.a. 18/33 13/31 p=0.838$
Disease duration (months) n.a. 26 [19-60] 29 [21-58] p=0.505$
BMI, Body mass index; WC, Waist circumference; FPG, Fasting plasma glucose; 2hPG, 2-h post-OGTT plasma glucose; FPI, Fasting 
plasma insulin; 2hPI, 2-h post-OGTT plasma insulin; HOMA-IR, homeostatic model of insulin resistance; HbA1c, glycated hemoglo-
bin; ISI, insulin sensitivity index; EISI, early insulin sensitivity index; NGT, normal glucose tolerance; IFG, impaired fasting glucose; 
IGT, impaired glucose tolerance.
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insulin resistance indices (HOMA-IR, ISI 
(Belfiore) and EISI (Stumvoll) impairment 
(data not shown). Significant predictors 
were then assessed in multivariate analy-
sis adjusted for sex and prednisone use; 
BMI was the single variable associated 
with FPG, FPI and HOMA-IR elevation 
(β>0.442, p<0.042 for all). Prednisone use 
was the single predictor of 2hPG eleva-
tion (β=0.371, p<0.016), while we failed 
to identify predictors of impaired 2hPI, 
Hb1Ac, ISI (Belfiore) and EISI (Stumv-
oll). We have also checked for the effect 
of citrullinated peptide antibody status on 
glucose metabolism. No differences could 
be detected between seropositive (N 37) 
and seronegative (N 16) patients (data not 
shown).
We performed the same analysis for PsA 
patients; predictors (age, BMI, WC, ESR, 
CRP, prednisone daily dose, disease dura-
tion, disease activity) of FPG, 2hPG, FPI, 
2hPI, Hb1Ac elevation and insulin resist-
ance indices (HOMA-IR, ISI and EISI) 
impairment were assessed in univariate 
analysis (data not shown). Significant pre-
dictors were then included in a multivariate 
analysis model adjusted for sex and pred-
nisone use. Disease duration was the only 
predictor of 2hPI elevation and ISI/EISI 
impairment (p<0.03).
Univariate and multivariate analysis were 
performed stratifying both RA and PsA pa-
tients according to disease activity. Results 
of univariate analysis are reported in Tables 
II, III and IV.
Variables with statistically significant as-
sociations were included in multivariate 
models adjusted for sex and prednisone 
use. Considering RA patients with residual 
disease activity, FPI elevation was pre-
dicted by ESR alone (β=0.459, p=0.047); 
accordingly, HOMA-IR was predicted by 
ESR and age (β=0.445, p=0.020; β=0.432, 
p=0.028, respectively). 2hPG and 2hPI 
were predicted by CRP alone (β=0.915, 
p=0.0003 and β=0.772, p=0.0006); accord-
ingly, ISI and EISI were predicted by CRP 
and age (ISI: CRP, β=-0.787, p=0.0006; 
Age β=-0.382, p=0.042. EISI: CRP β=-
0.797, p=0.0001; Age β=-0.419, p=0.007). 
Finally, Hb1Ac was only related to age 
Table III - Predictors of glucose metabolism in RA: univariate analysis, associations with disease activity scores.
Rheumatoid Arthritis in remission (DAS28 < 
2.6)
Rheumatoid Arthritis with residual activity 
(DAS28 ≥ 2.6)
CDAI SDAI DAS28 CDAI SDAI DAS28
FPG 
(mmol/l)
0.202
p=0.259
-0.148
p=0.411
-0.117
p=0.532
-0.427
p=0.077
-0.339
p=0.169
-0.354
p=0.163
2hPG 
(mmol/l)
0.218
p=0.222
-0.095
p=0.598
-0.037
p=0.843
-0.236
p=0.346
-0.151
p=0.550
-0.088
p=0.736
FPI 
(pmol/l)
-0.010
p=0.954
-0.119
p=0.509
-0.078
p=0.678
0.308
p=0.214
-0.111
p=0.662
-0.177
p=0.496
2hPI 
(pmol/l)
0.165
p=0.358
-0.125
p=0.488
-0.042
p=0.822
-0.071
p=0.780
-0.005
p=0.984
-0.008
p=0.975
HOMA-IR -0.022p=0.903
-0.155
p=0.390
-0.108
p=0.564
0.187
p=0.458
-0.185
p=0.461
-0.249
p=0.336
HbA1c
(mmol/mol)
0.143
p=0.458
0.188
p=0.328
0.294
p=0.137
-0.164
p=0.514
-0.245
p=0.327
-0.211
p=0.416
ISI 
(Belfiore)
-0.108
p=0.550
0.006
p=0.974
-0.057
p=0.760
-0.031
p=0.903
-0.083
p=0.743
-0.060
p=0.820
EISI 
(Stumvoll)
-0.104
p=0.563
0.142
p=0.431
0.070
p=0.707
-0.017
p=0.948
0.108
p=0.669
-0.110
p=0.674
BMI, Body mass index; WC, Waist circumference; ESR, erythrocyte sedimentation rate; CRP, C-reactive 
protein; PDN, prednisone; CDAI, clinical disease activity index; SDAI, simplified disease activity index; 
DAS28, disease activity score 28; FPG, Fasting plasma glucose; 2hPG, 2-h post-OGTT plasma glucose; 
FPI, Fasting plasma insulin; 2hPI, 2-h post-OGTT plasma insulin; HOMA-IR, homeostatic model of insulin 
resistance; HbA1c, glycated hemoglobin; ISI, insulin sensitivity index; EISI, early insulin sensitivity index.
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(β=0.542, p=0.007). In RA patients with no 
residual disease activity, as expected, the 
most relevant predictor for impairment of 
glucose and insulin metabolism was BMI, 
which was a significant predictor of FPG, 
FPI, HOMA-IR, Hb1Ac and ISI (β=0.589, 
p=0.004; β=0.659, p=0.007; β=0.726, 
p=0.002; β=0.553, p=0.004; -0.392, 
p=0.044 respectively); furthermore, pred-
nisone use predicted FPG and 2hPG eleva-
tion (β=0.295, p=0.027; β=0.480, p=0.005 
respectively). 
Considering PsA patients with residual 
disease activity, no significant predictor 
was identified at multivariate analysis; in 
patients with no residual disease activity, 
WC was the only significant predictor of 
ISI impairment (β=-0.452, p=0.042), while 
age predicted Hb1Ac elevation (β=0.439, 
p=0.044).
n	 DISCUSSION
Growing evidence has related insulin re-
sistance to inflammatory arthritis (2, 3); in 
this OGTT-based study we have investi-
gated this association both in RA and PsA. 
Interestingly, we found that the correlation 
between inflammation and insulin sensitiv-
ity is limited to patients with active RA, 
whereas it is not demonstrable in PsA.
Looking at the indices of glucose metabo-
lism in RA patients, BMI was the strongest 
predictor of insulin resistance, in agree-
ment with the literature suggesting that 
obesity is the main determinant of glucose 
tolerance (16). On the other hand, pred-
nisone use was the only predictor of 2hPG, 
as expected considering the detrimental 
impact of prednisone on insulin sensitiv-
ity. In PsA, disease duration predicted 
higher insulin plasma concentration after 
OGTT; prednisone use was less relevant, 
its effect being more limited in PsA than 
in RA. Interestingly, we were not able to 
confirm previous studies which proved an 
altered insulin sensitivity in RA and PsA 
with respect to a control population (2, 17); 
recently, results consistent with ours have 
been reported in a population of patients 
affected by early RA, the insulin sensitivity 
of whom was not different from a control 
group (18). It could be argued that in our 
study the high percentage of patients in 
clinical remission may have created a bias; 
to avoid it, we evaluated whether inflam-
mation and disease activity were able to 
predict the result of OGTT in those patients 
with residual disease activity. Interestingly, 
in RA, ESR was in direct relationship with 
baseline blood glucose levels and, accord-
ingly, the HOMA-IR was higher in the 
presence of high ESR values. On the con-
trary, CRP was a predictor of the response 
to a glucose load, being directly related 
to ISI and EISI. The reason why different 
inflammatory markers predict different 
alterations of glucose metabolism is un-
clear. One possible explanation is that ESR 
marks inflammation on a longer time scale 
than CRP which, conversely, is a marker of 
inflammation spanning a shorter period. 
In PsA the above mentioned associations 
were not confirmed, a finding that needs 
to be discussed at the light of the current 
literature. Recently, in fact, different au-
thors have convincingly demonstrated an 
increased risk of type 2 diabetes mellitus 
(T2DM) in patients affected by PsA with 
respect to either a matched control group 
or patients affected by RA (19, 20). Two 
reasons may exist to explain this apparent 
discrepancy. Firstly, the patients enrolled 
in these studies had a significantly longer 
follow-up than our cohort PsA patients; 
secondly, for the present study we exclud-
ed PsA patients with a defined diagnosis 
of T2DM. As a matter of fact, we did not 
investigate incidence and prevalence of 
T2DM in PsA at all, since our aim was to 
give a cross-sectional picture of the asso-
ciation between inflammation and insulin 
sensitivity. On the other hand, the reason(s) 
why inflammatory markers are less predic-
tive of glucose metabolism impairment in 
PsA than in RA could be: i) the heteroge-
neity of PsA; and/or ii) the fact that in PsA 
inflammatory markers reflect disease ac-
tivity less well, especially among patients 
whose disease is mainly characterized by 
enthesopathy manifestations. Due to these 
limitations, we cannot entirely dismiss the 
hypothesis that a larger sample and a more 
disease-specific stratification of activ-
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ity (cutaneous, articular or enthesopathy) 
could disclose an association between in-
flammation and insulin sensitivity in PsA 
as well as in RA.
Our study has other limitations. As just 
mentioned, its nature is explorative, with 
a relatively small sample size and short 
follow-up; a larger population is required 
to confirm our results and to allow a more 
comprehensive analysis. Specifically, it 
would be interesting to evaluate the re-
sponse to OGTT, grouping patients accord-
ing to the type of anti-rheumatic treatment 
in use, since it has been shown that some 
of the classical and biological DMARDs 
commonly employed in clinical practice 
have a positive impact on insulin sensitiv-
ity (5, 6, 21). On the other hand, we would 
like to point out that a novel aspect of the 
study is the comparison of glucose me-
tabolism between RA and PsA. These two 
conditions are characterized by a very dif-
ferent biological behavior, which arguably 
is reflected on relevant differences in co-
morbidities. 
n	 CONCLUSIONS
In conclusion, appropriate management of 
comorbidities demands that an altered glu-
cose metabolism should be ruled out for all 
patients affected by inflammatory arthritis. 
However, to interpret correctly the results 
of metabolic studies, clinicians need to be 
aware that the impact of disease activity is 
not necessarily similar for all rheumatic 
diseases. Our data indicate that they should 
be particularly alerted to its influence on 
patients with RA, among whom not only 
fasting insulin sensitivity, but also the re-
sponse to an oral glucose load bears a rela-
tionship with inflammatory markers.
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